Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OPTR

(OPTR) (OPTR) Stock Price, News & Analysis

(OPTR) logo

About (OPTR) Stock (NASDAQ:OPTR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive OPTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (OPTR) and its competitors with MarketBeat's FREE daily newsletter.

OPTR Stock News Headlines

IBFD launches the 2023 Yearbook on Taxpayers’ Rights
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Optimer Pharmaceuticals Inc (OPTR)
IBFD launches the 2022 Yearbook on Taxpayers’ Rights
See More Headlines

OPTR Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that (OPTR) investors own include Geron (GERN), Glacier Bancorp (GBCI), EPIRUS Biopharmaceuticals (EPRSQ), 8X8 (EGHT), Corner Growth Acquisition (COOL), Compass Diversified (CODI) and Cello Health plc (CLL.L) (CLL).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:OPTR
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:OPTR) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners